Article
Biochemistry & Molecular Biology
Shen-Chih Wang, Xiang-Yu Wang, Chung-Te Liu, Ruey-Hsing Chou, Zhen Bouman Chen, Po-Hsun Huang, Shing-Jong Lin
Summary: Linagliptin exhibits protective effects against endothelial inflammation and microvascular thrombosis in a mouse model of sepsis, and these effects are independent of blood glucose level.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Endocrinology & Metabolism
Xianling Zhou, Heng Shi, Shiping Zhu, Haixia Wang, Shengyun Sun
Summary: This study evaluated the therapeutic effect and safety of combining dipeptidyl peptidase-4 inhibitors with insulin in patients with type 2 diabetes and chronic kidney disease. The results showed that combination treatment resulted in lower levels of glycated hemoglobin and insulin dose compared to the control groups, without increasing adverse events or hypoglycemia. Additional high-quality randomized controlled trials are needed to confirm the protective effects of this treatment on kidney and cardiovascular outcomes.
JOURNAL OF DIABETES INVESTIGATION
(2022)
Article
Cardiac & Cardiovascular Systems
Qu Chen, Dandan Jiang, Zhonggui Shan
Summary: This study investigated the effects of dipeptidyl peptidase-4 inhibitors (DPP4i) on the progression of type B intramural hematoma (IMHB) in patients with diabetes mellitus (DM). The study found that DM patients with IMHB who received DPP4i treatment had lower aorta-related mortality and a more benign progression compared to those who did not receive DPP4i or those without DM. Furthermore, a higher eosinophil count and a lower neutrophil to lymphocyte ratio (NLR) were identified as potential protective factors that may explain the therapeutic benefits of DPP4i.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2022)
Article
Immunology
Yuichiro Iwamoto, Takatoshi Anno, Katsumasa Koyama, Fumiko Kawasaki, Kohei Kaku, Koichi Tomoda, Seiko Sugiyama, Yumi Aoyama, Hideaki Kaneto
Summary: DPP-4 inhibitors are closely associated with bullous pemphigoid (BP) and may lead to disruption of immune tolerance. Checking autoimmune antibodies may be important in DPP-4i-related BP, even when symptoms improve.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Medicine, General & Internal
Eugene Yu-Chuan Kang, Chunya Kang, Wei-Chi Wu, Chi-Chin Sun, Kuan-Jen Chen, Chi-Chun Lai, Tien-Hsing Chen, Yih-Shiou Hwang
Summary: This study suggests that add-on dipeptidyl peptidase-4 inhibitor (DPP4i) therapy in patients with type 2 diabetes may be associated with the progression of diabetic retinopathy (DR), leading to increased risks of vitreous hemorrhage and macular edema. Further research is needed to confirm these findings and explore the potential impact of DPP4i therapy on DR progression in patients with type 2 diabetes.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Endocrinology & Metabolism
Marcel H. A. Muskiet, Lennart Tonneijck, Mark M. Smits, Mark H. H. Kramer, D. Margriet Ouwens, Bolette Hartmann, Jens J. Holst, A. H. Jan Danser, Jaap A. Joles, Daniel H. van Raalte
Summary: In adults with type 2 diabetes, the dipeptidyl peptidase-4 inhibitor linagliptin did not reduce postprandial hyperfiltration compared to the sulphonylurea glimepiride. However, it appeared to increase the filtration fraction after a meal by potentially raising blood pressure or efferent arteriolar resistance.
DIABETES OBESITY & METABOLISM
(2022)
Review
Endocrinology & Metabolism
Shangyu Chai, Ruya Zhang, Ye Zhang, Richard David Carr, Yiman Zheng, Swapnil Rajpathak, Miao Yu
Summary: This meta-analysis suggests that dipeptidyl peptidase-4 (DPP4) inhibitors are more effective than other oral antidiabetic drugs in reducing glycemic variability, as measured by mean amplitude of glycemic excursions (MAGE), in type 2 diabetes mellitus patients without concurrent insulin treatments.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Article
Endocrinology & Metabolism
Julio Rosenstock, Ahmed A. Kolkailah, Darren K. McGuire, Mark A. Espeland, Michaela Mattheus, Egon Pfarr, Soren S. Lund, Nikolaus Marx
Summary: The CAROLINA trial showed the non-inferiority of linagliptin compared to glimepiride in terms of major adverse cardiovascular events in patients with early type 2 diabetes and increased cardiovascular risk. The study also demonstrated that linagliptin significantly reduced the hypoglycaemic burden across all categories, including severe episodes.
DIABETES OBESITY & METABOLISM
(2023)
Article
Urology & Nephrology
Yang Xu, Edouard L. Fu, Catherine M. Clase, Faizan Mazhar, Meg J. Jardine, Juan J. Carrero
Summary: In this study, it was found that glucagon-like peptide-1 receptor agonists (GLP1RA) were associated with a lower risk of kidney outcomes compared to dipeptidyl peptidase-4 inhibitors (DPP4i). The reductions in both kidney outcomes and major adverse cardiovascular events (MACE) were similar in magnitude to those reported in large cardiovascular outcome trials.
KIDNEY INTERNATIONAL
(2022)
Article
Cardiac & Cardiovascular Systems
Yuka Shiheido-Watanabe, Yasuhiro Maejima, Takeshi Kasama, Natsuko Tamura, Shun Nakagama, Yusuke Ito, Kenzo Hirao, Mitsuaki Isobe, Tetsuo Sasano
Summary: The study demonstrated the mechanism of ameliorating experimental autoimmune myocarditis by linagliptin, showing that it reduces Th17 cells infiltration and oxidative stress in EAM hearts. It also found that the interaction between DPP-4 and cathepsin G plays a detrimental role by suppressing SerpinA3N activity.
JACC-BASIC TO TRANSLATIONAL SCIENCE
(2021)
Article
Public, Environmental & Occupational Health
Wei-Hao Hsu, Shu-Ping Sue, Hsiu-Ling Liang, Chin-Wei Tseng, Hsiu-Chu Lin, Wei-Lun Wen, Mei-Yueh Lee
Summary: The study found that the use of DPP-4 inhibitors was associated with a lower risk of hepatocellular carcinoma in patients with type 2 diabetes and chronic HCV infection.
FRONTIERS IN PUBLIC HEALTH
(2021)
Article
Endocrinology & Metabolism
Shangyu Chai, Ruya Zhang, Ye Zhang, Richard David Carr, Yiman Zheng, Swapnil Rajpathak, Linong Ji
Summary: This meta-analysis summarizes the effects of DPP4 inhibitors on glucagon levels in patients with type 2 diabetes mellitus (T2DM). The results show that DPP4 inhibitors can significantly reduce postprandial glucagon levels in T2DM patients.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Xi Chen, Bin Xue, Shadma Wahab, Armiya Sultan, Mohammad Khalid, Song Yang
Summary: In this study, a potential DPP4 inhibitor, SRT2183, was identified using computational methods and validated through molecular docking and molecular dynamics simulations.
JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
(2023)
Article
Endocrinology & Metabolism
Young Choi, Seung-Hyun Ko, Kiyuk Chang, Ki Dong Yoo, Sang-Hyun Ihm
Summary: This study evaluated the effect of a dipeptidyl peptidase-4 inhibitor (DPP-4i) on obstructive coronary artery disease (OCAD) progression in patients with type 2 diabetes mellitus (T2DM) receiving insulin therapy. The results showed that the use of DPP-4i was associated with a lower incidence of newly developed OCAD compared to no DPP-4i use. Therefore, adding DPP-4i therapy to insulin treatment in T2DM patients can effectively prevent coronary artery disease progression.
JOURNAL OF DIABETES
(2023)
Article
Endocrinology & Metabolism
Xin Wei, Yu Bai, Zhuo Wang, Xiaohong Zheng, Zening Jin, Xin Liu
Summary: The study found that DPP-4 inhibitors did not significantly change leptin concentrations in patients with type 2 diabetes mellitus and did not have stronger effects compared to traditional antidiabetic agents. The meta-analysis results were powerful and stable after sensitivity analysis.
DIABETOLOGY & METABOLIC SYNDROME
(2021)